Asrani, S. K., Devarbhavi, H., Eaton, J. & Kamath, P. S. Burden of liver diseases in the world. J. Hepatol. 70, 151–171 (2019).
Shiina, S. et al. Liver disease trends in the Asia-Pacific region for the next 50 years. Clin. Mol. Hepatol. 31, 671–684 (2025).
Gan, C. et al. Liver diseases: Epidemiology, causes, trends and predictions. Sig Transduct. Target Ther. 10, 33 (2025).
Zhao, Y. et al. Global burden of chronic liver disease and temporal trends: A population-based analysis from 1990 to 2021 with projections to 2050. Liver Int. 45, e70155 (2025).
Wang, R. et al. Gut microbiome, liver immunology, and liver diseases. Cell Mol. Immunol. 18, 4–17 (2021).
Wang, L., Cao, Z., Zhang, L., Li, J. & Lv, W. The role of gut microbiota in some liver diseases: From an immunological perspective. Front Immunol. 13, 923599 (2022).
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
Zhang, L. L., Deng, W. H. & Wang, W. X. Characteristics and research progress on the role of intestinal fungi in chronic liver disease]. Zhonghua Gan Zang Bing. Za Zhi 30, 1285–1288 (2022).
Mohammadi, R., Morovati, H. & Safari, F. The human mycobiome: a critical yet understudied component of health and disease. Microbiology 171, 001631 (2025).
Zeng, S. & Schnabl, B. Roles for the mycobiome in liver disease. Liver Int 42, 729–741 (2022).
Kong, H. H. & Segre, J. A. Cultivating fungal research. Science 368, 365–366 (2020).
Zeng, S. & Schnabl, B. Gut mycobiome alterations and implications for liver diseases. PLoS Pathog. 20, e1012377 (2024).
Hartmann, P. & Schnabl, B. Fungal infections and the fungal microbiome in hepatobiliary disorders. J. Hepatol. 78, 836–851 (2023).
Lang, S. et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 71, 522–538 (2020).
Demir, M. et al. The fecal mycobiome in non-alcoholic fatty liver disease. J. Hepatol. 76, 788–799 (2022).
Yang, A.-M. et al. Intestinal fungi contribute to development of alcoholic liver disease. J. Clin. Invest 127, 2829–2841 (2017).
Chu, H. et al. The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. J. Hepatol. 72, 391–400 (2020).
Patin, E. C., Thompson, A. & Orr, S. J. Pattern recognition receptors in fungal immunity. Semin Cell Dev. Biol. 89, 24–33 (2019).
Jensen, O., Trujillo, E., Hanson, L. & Ost, K. S. Controlling Candida: immune regulation of commensal fungi in the gut. Infect. Immun. 92, e0051623 (2024).
You, N., Zhuo, L., Zhou, J., Song, Y. & Shi, J. The role of intestinal fungi and its metabolites in chronic liver diseases. Gut Liver 14, 291–296 (2020).
Nash, A. K. et al. The gut mycobiome of the human microbiome project healthy cohort. Microbiome 5, 153 (2017).
Hallen-Adams, H. E., Kachman, S. D., Kim, J., Legge, R. M. & Martínez, I. Fungi inhabiting the healthy human gastrointestinal tract: A diverse and dynamic community. Fungal Ecol. 15, 9–17 (2015).
Hsu, C. L. & Schnabl, B. The gut-liver axis and gut microbiota in health and liver disease. Nat. Rev. Microbiol 21, 719–733 (2023).
Deng, X. et al. Composition, influencing factors, and effects on host nutrient metabolism of fungi in gastrointestinal tract of monogastric animals. Anim. (Basel) 15, 710 (2025).
Flint, H. J., Scott, K. P., Louis, P. & Duncan, S. H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577–589 (2012).
Leonardi, I. et al. Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity. Cell 185, 831–846.e14 (2022).
Li, D. et al. Microbial biogeography and core microbiota of the rat digestive tract. Sci. Rep. 8, 45840 (2017).
Cui, L., Morris, A. & Ghedin, E. The human mycobiome in health and disease. Genome Med 5, 63 (2013).
Sun, Y. et al. Population-level configurations of gut mycobiome across 6 ethnicities in urban and rural China. Gastroenterology 160, 272–286.e11 (2021).
Buttler, L. et al. Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation. Gut Microbes 17, 2487209 (2025).
Guo, Y. et al. A diet high in sugar and fat influences neurotransmitter metabolism and then affects brain function by altering the gut microbiota. Transl. Psychiatry 11, 328 (2021).
Chopyk, D. M. & Grakoui, A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders. Gastroenterology 159, 849–863 (2020).
Tripathi, A. et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15, 397–411 (2018).
Zheng, Z. & Wang, B. The gut-liver axis in health and disease: The role of gut microbiota-derived signals in liver injury and regeneration. Front Immunol. 12, 775526 (2021).
Jiang, L. et al. The gut mycobiome: a novel player in chronic liver diseases. J. Gastroenterol. 56, 1–11 (2021).
Meroni, M., Longo, M. & Dongiovanni, P. Alcohol or gut microbiota: Who is the guilty? Int J. Mol. Sci. 20, 4568 (2019).
Asrani, S. K., Mellinger, J., Arab, J. P. & Shah, V. H. Reducing the global burden of alcohol-associated liver disease: A blueprint for action. Hepatology 73, 2039–2050 (2021).
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L. & Lucey, M. R. Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. Hepatology 71, 306–333 (2020).
Bataller, R., Arab, J. P. & Shah, V. H. Alcohol-associated hepatitis. N. Engl. J. Med 387, 2436–2448 (2022).
Dukić, M. et al. Alcohol, inflammation, and microbiota in alcoholic liver disease. Int J. Mol. Sci. 24, 3735 (2023).
Leclercq, S. et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc. Natl. Acad. Sci. USA 111, E4485–E4493 (2014).
Gao, B., Ahmad, M. F., Nagy, L. E. & Tsukamoto, H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 70, 249–259 (2019).
Zeng, S. et al. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe 31, 389–404.e7 (2023).
Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019).
Hartmann, P. et al. Dynamic changes of the fungal microbiome in alcohol use disorder. Front Physiol. 12, 699253 (2021).
Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32–S42 (2023).
Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).
Zhou, J. et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology 71, 1851–1864 (2020).
Fang, J. et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect. Microbiol 12, 997018 (2022).
Loomba, R. & Adams, L. A. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885–1888 (2019).
Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32–S50 (2025).
You, N. et al. Fecal fungi dysbiosis in nonalcoholic fatty liver disease. Obes. (Silver Spring) 29, 350–358 (2021).
Viebahn, G. et al. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes 16, 2307586 (2024).
Scarlata, G. G. M. et al. Gut microbiota changes in metabolic dysfunction-associated steatohepatitis and inflammatory bowel disease: Common pathogenic features. Curr. Issues Mol. Biol. 47, 847 (2025).
Zhou, S. et al. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis. Science 388, eadp5540 (2025).
Liu, Y. T., Li, Y. Q. & Wang, Y. Z. Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing. Za Zhi 24, 921–926 (2016).
Cooper, J. et al. Incidence and prevalence of primary sclerosing cholangitis: A meta-analysis of population-based studies. Inflamm. Bowel Dis. 30, 2019–2026 (2024).
Olfatifar, M. et al. The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: An updated meta-analysis and modeling study. PLoS One 20, e0322479 (2025).
Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045–2055 (2013).
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W. & Hudson, M. Primary sclerosing cholangitis. Lancet 391, 2547–2559 (2018).
Sirpal, S. & Chandok, N. Primary sclerosing cholangitis: Diagnostic and management challenges. Clin. Exp. Gastroenterol. 10, 265–273 (2017).
Shah, A., Macdonald, G. A., Morrison, M. & Holtmann, G. Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: A conceptional framework. Am. J. Gastroenterol. 115, 814–822 (2020).
Lv, L.-X. et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ. Microbiol 18, 2272–2286 (2016).
Tang, R. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut 67, 534–541 (2018).
Furukawa, M. et al. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. Hepatol. Res 50, 840–852 (2020).
Abe, K. et al. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 13, e0198757 (2018).
Wang, Y., Zhao, Z., Lu, H., Zhang, J. & Huang, F. Fungal infection involvement in primary biliary cirrhosis: A review of 2 cases. Exp. Ther. Med 13, 489–494 (2017).
Samonakis, D. N., Chatzicostas, C., Vardas, E., Roussomoustakaki, M. & Kouroumalis, E. A. Increased incidence of fungal infections in advanced primary biliary cirrhosis. J. Clin. Gastroenterol. 36, 369 (2003).
Muratori, P. et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132, 473–476 (2003).
Lee, M. J. A review of liver fibrosis and cirrhosis regression. J. Pathol. Transl. Med 57, 189–195 (2023).
Opulente, D. A. et al. Genomic factors shape carbon and nitrogen metabolic niche breadth across Saccharomycotina yeasts. Science 384, eadj4503 (2024).
Kulaksiz, H. et al. Biliary candida infections in primary sclerosing cholangitis. J. Hepatol. 45, 711–716 (2006).
Rudolph, G. et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J. Hepatol. 51, 149–155 (2009).
Bacher, P. et al. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against candida albicans. Cell 176, 1340–1355.e15 (2019).
Katt, J. et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology 58, 1084–1093 (2013).
Harada, K. et al. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin. Exp. Immunol. 157, 261–270 (2009).
Lan, R. Y. Z. et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J. Autoimmun. 32, 43–51 (2009).
Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J. Hepatol. 72, 558–577 (2020).
Trebicka, J., Reiberger, T. & Laleman, W. Gut-liver axis links portal hypertension to acute-on-chronic liver failure. Visc. Med. 34, 270–275 (2018).
Tandon, P. & Garcia-Tsao, G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 28, 26–42 (2008).
Righi, E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World J. Gastroenterol. 24, 4311–4329 (2018).
Lahmer, T. et al. Fungal ‘colonisation’ is associated with increased mortality in medical intensive care unit patients with liver cirrhosis. Mycopathologia 179, 63–71 (2015).
Bajaj, J. S. et al. Fungal dysbiosis in cirrhosis. Gut 67, 1146–1154 (2018).
Perlin, C. M., Longo, L., Keingeski, M. B., Picon, R. V. & Álvares-da-Silva, M. R. Gut mycobiota changes in liver diseases: A systematic review. Med Mycol. 61, myad071 (2023).
Chen, Y. et al. Correlation between gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. Diagn. Microbiol Infect. Dis. 70, 492–498 (2011).
Park, W. B. et al. Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am. J. Med 119, 169–171 (2006).
Gravito-Soares, M., Gravito-Soares, E., Lopes, S., Ribeiro, G. & Figueiredo, P. Spontaneous fungal peritonitis: a rare but severe complication of liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 29, 1010–1016 (2017).
Bartoletti, M. et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J. Hepatol. 61, 51–58 (2014).
Bajaj, J. S. et al. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. Am. J. Gastroenterol. 113, 556–563 (2018).
Papp, M. et al. Presence of anti-microbial antibodies in liver cirrhosis-a tell-tale sign of compromised immunity? PLoS One 5, e12957 (2010).
Hwang, S. Y. et al. Spontaneous fungal peritonitis: A severe complication in patients with advanced liver cirrhosis. Eur. J. Clin. Microbiol Infect. Dis. 33, 259–264 (2014).
Lahmer, T., Brandl, A., Rasch, S., Schmid, R. M. & Huber, W. Fungal peritonitis: Underestimated disease in critically ill patients with liver cirrhosis and spontaneous peritonitis. PLoS One 11, e0158389 (2016).
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).
Dutta, R. & Mahato, R. I. Recent advances in hepatocellular carcinoma therapy. Pharm. Ther. 173, 106–117 (2017).
Yang, J. D. & Heimbach, J. K. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 371, m3544 (2020).
Bertuccio, P. et al. Global trends and predictions in hepatocellular carcinoma mortality. J. Hepatol. 67, 302–309 (2017).
Xie, Y. et al. GULP1, a multifaceted diagnostic biomarker and potential therapeutic target in hepatocellular carcinoma: Editorial on ‘GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma. Clin. Mol. Hepatol. 32, 413–415 (2026).
Han, J. E. et al. Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on ‘MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation. Clin. Mol. Hepatol. 32, 436–438 (2026).
Kew, M. C. Aflatoxins as a cause of hepatocellular carcinoma. J. Gastrointestin Liver Dis. 22, 305–310 (2013).
Jiang, S. et al. Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease. Sci. China Life Sci. 67, 1183–1198 (2024).
Zhang, L. et al. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J. Transl. Med 21, 126 (2023).
Liu, Z. et al. Intestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6. Front Microbiol 13, 812771 (2022).
Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).
Zeng, S. et al. Malassezia restricta promotes alcohol-induced liver injury. Hepatol. Commun. 7, e0029 (2023).
Ulusan, M. et al. Saccharomyces boulardii mitigates fructose-induced non-alcoholic fatty liver in rats. Med. (Kaunas.) 60, 1713 (2024).
Yu, L. et al. Saccharomyces boulardii administration changes gut microbiota and attenuates D-galactosamine-induced liver injury. Sci. Rep. 7, 1359 (2017).
Abarenkov, K. et al. The UNITE database for molecular identification and taxonomic communication of fungi and other eukaryotes: Sequences, taxa and classifications reconsidered. Nucleic Acids Res. 52, D791–D797 (2024).
Fosso, B. et al. ITSoneDB: a specialized ITS1 database for amplicon-based metagenomic characterization of environmental fungal communities. EMBnet. J. 18, 90 (2012).
Suhr, M. J. & Hallen-Adams, H. E. The human gut mycobiome: pitfalls and potentials-a mycologist’s perspective. Mycologia 107, 1057–1073 (2015).
Doan, H. T. et al. Candida tropicalis alters barrier permeability and claudin-1 organization in intestinal epithelial cells. J. Physiol. Investig. 68, 67 (2025).
Morelli, M. & Queiroz, K. Breaking Barriers: Candidalysin disrupts epithelial integrity and induces inflammation in a gut-on-chip model. Toxins (Basel) 17, 89 (2025).
Allert, S. et al. Candida albicans-induced epithelial damage mediates translocation through intestinal barriers. mBio 9, https://doi.org/10.1128/mbio.00915-18 (2018).
Özdirik, B. & Schnabl, B. Microbial players in primary sclerosing cholangitis: Current evidence and concepts. Cell Mol. Gastroenterol. Hepatol. 17, 423–438 (2024).
Romani, L. Immunity to fungal infections. Nat. Rev. Immunol. 11, 275–288 (2011).
Brown, G. D. & Gordon, S. Fungal beta-glucans and mammalian immunity. Immunity 19, 311–315 (2003).
Plato, A. et al. Pattern recognition receptors in antifungal immunity. Semin Immunopathol. 37, 97–106 (2015).
Theel, E. S. & Doern, C. D. β-D-glucan testing is important for diagnosis of invasive fungal infections. J. Clin. Microbiol 51, 3478–3483 (2013).
Kondori, N., Edebo, L. & Mattsby-Baltzer, I. Circulating beta (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin. Diagn. Lab Immunol. 11, 344–350 (2004).
Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322–335 (2008).
Chen, L. et al. The role of gut bacteria and fungi in alcohol-associated liver disease. Front Med (Lausanne) 9, 840752 (2022).
Iliev, I. D. & Leonardi, I. Fungal dysbiosis: Immunity and interactions at mucosal barriers. Nat. Rev. Immunol. 17, 635–646 (2017).
Drummond, R. A. et al. CARD9+ microglia promote antifungal immunity via IL-1β- and CXCL1-mediated neutrophil recruitment. Nat. Immunol. 20, 559–570 (2019).
Mirea, A.-M. et al. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol. Med 25, 16 (2019).
Ma, D. W. et al. Innate immune system in the pathogenesis of non-alcoholic fatty liver disease. Nutrients 15, 2068 (2023).
Mbaye, B. et al. Endogenous ethanol and triglyceride production by gut pichia kudriavzevii, candida albicans and candida glabrata yeasts in non-alcoholic steatohepatitis. Cells 11, 3390 (2022).
Mims, T. S. et al. The gut mycobiome of healthy mice is shaped by the environment and correlates with metabolic outcomes in response to diet. Commun. Biol. 4, 281 (2021).
Sudun, W. ulijideligen, Arakawa, K., Miyamoto, M. & Miyamoto, T. Interaction between lactic acid bacteria and yeasts in airag, an alcoholic fermented milk. Anim. Sci. J. 84, 66–74 (2013).
Bivin, W. S. & Heinen, B. N. Production of ethanol from infant food formulas by common yeasts. J. Appl Bacteriol. 58, 355–357 (1985).
Bayoumy, A. B., Mulder, C. J. J., Mol, J. J. & Tushuizen, M. E. Gut fermentation syndrome: A systematic review of case reports. U. Eur. Gastroenterol. J. 9, 332–342 (2021).
Grózer, Z. et al. Candida parapsilosis produces prostaglandins from exogenous arachidonic acid and OLE2 is not required for their synthesis. Virulence 6, 85–92 (2015).
Noverr, M. C., Phare, S. M., Toews, G. B., Coffey, M. J. & Huffnagle, G. B. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69, 2957–2963 (2001).
Sun, S. et al. Therapeutic manipulation of gut microbiota by polysaccharides of Wolfiporia cocos reveals the contribution of the gut fungi-induced PGE2 to alcoholic hepatic steatosis. Gut Microbes 12, 1830693 (2020).
Wang, W., Zhong, X. & Guo, J. Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review). Int J. Mol. Med 47, 114 (2021).
Henkel, J. et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Sci. Rep. 8, 16127 (2018).
Smeekens, S. P. et al. The Candida Th17 response is dependent on mannan- and beta-glucan-induced prostaglandin E2. Int Immunol. 22, 889–895 (2010).
Gagliardi, M. C. et al. Endogenous PGE2 promotes the induction of human Th17 responses by fungal ß-glucan. J. Leukoc. Biol. 88, 947–954 (2010).
Lafdil, F., Miller, A. M., Ki, S. H. & Gao, B. Th17 cells and their associated cytokines in liver diseases. Cell Mol. Immunol. 7, 250–254 (2010).
Kasper, L. et al. The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat. Commun. 9, 4260 (2018).
Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037–1046 (2017).
He, K. et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development. Oncotarget 8, 37657–37672 (2017).
Magnussen, A. & Parsi, M. A. Aflatoxins, hepatocellular carcinoma and public health. World J. Gastroenterol. 19, 1508–1512 (2013).
Hamid, A. S., Tesfamariam, I. G., Zhang, Y. & Zhang, Z. G. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol. Lett. 5, 1087–1092 (2013).
Kew, M. C. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 23, 405–409 (2003).
Heisel, T. et al. High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut. mSphere 2, e00351-17 (2017).
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E. & Cotter, P. D. Antifungal peptides as therapeutic agents. Front Cell Infect. Microbiol 10, 105 (2020).
Kombrink, A. et al. Induction of antibacterial proteins and peptides in the coprophilous mushroom Coprinopsis cinerea in response to bacteria. ISME J. 13, 588–602 (2019).
Shao, T.-Y. et al. Commensal candida albicans positively calibrates systemic Th17 immunological responses. Cell Host Microbe 25, 404–417.e6 (2019).
Chen, Y.-H. et al. Rewilding of laboratory mice enhances granulopoiesis and immunity through intestinal fungal colonization. Sci. Immunol. 8, eadd6910 (2023).
García, C. et al. The human gut microbial metabolome modulates fungal growth via the TOR signaling pathway. mSphere 2, e00555-17 (2017).
Alonso-Roman, R. et al. Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat. Commun. 13, 3192 (2022).
Noverr, M. C. & Huffnagle, G. B. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun. 72, 6206–6210 (2004).
Lynch, A. S. & Robertson, G. T. Bacterial and fungal biofilm infections. Annu Rev. Med 59, 415–428 (2008).
van Leeuwen, P. T. et al. Interspecies Interactions between Clostridium difficile and Candida albicans. mSphere 1, e00187–16 (2016).
Chen, L. et al. Modulating phenylalanine metabolism by L. acidophilus alleviates alcohol-related liver disease through enhancing intestinal barrier function. Cell Biosci. 13, 24 (2023).
Wang, W., Gao, X., Niu, W., Yin, J. & He, K. Targeting Metabolism: Innovative Therapies for MASLD Unveiled. Int J. Mol. Sci. 26, 4077 (2025).
Kim, H. Y. & Rinella, M. E. Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment. Clin. Mol. Hepatol. 31, 753–770 (2025).
Szajewska, H., Konarska, Z. & Kołodziej, M. Probiotic bacterial and fungal strains: Claims with evidence. Dig. Dis. 34, 251–259 (2016).
Duman, D. G. et al. Saccharomyces boulardii ameliorates clarithromycin- and methotrexate-induced intestinal and hepatic injury in rats. Br. J. Nutr. 110, 493–499 (2013).
Li, M., Zhu, L., Xie, A. & Yuan, J. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38, 170–179 (2015).
Bourrie, B. C. T., Willing, B. P. & Cotter, P. D. The microbiota and health promoting characteristics of the fermented beverage kefir. Front Microbiol 7, 647 (2016).
González-Orozco, B. D., García-Cano, I., Jiménez-Flores, R. & Alvárez, V. B. Invited review: Milk kefir microbiota-Direct and indirect antimicrobial effects. J. Dairy Sci. 105, 3703–3715 (2022).
Eyre, D. W. et al. A candida auris outbreak and its control in an intensive care setting. N. Engl. J. Med 379, 1322–1331 (2018).
Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med 4, 165rv13 (2012).
Robbins, N., Wright, G. D. & Cowen, L. E. Antifungal drugs: the current armamentarium and development of new agents. Microbiol. Spectr. 4, 903–922 (2016).
Huang, H. et al. The mycobiome as integral part of the gut microbiome: crucial role of symbiotic fungi in health and disease. Gut Microbes 16, 2440111 (2024).
Bao, L., Zhang, Y., Zhang, G., Jiang, D. & Yan, D. Abnormal proliferation of gut mycobiota contributes to the aggravation of Type 2 diabetes. Commun. Biol. 6, 226 (2023).
Li, X. et al. Response to fungal dysbiosis by gut-resident CX3CR1+ mononuclear phagocytes aggravates allergic airway disease. Cell Host Microbe 24, 847–856.e4 (2018).
Wheeler, M. L. et al. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19, 865–873 (2016).
Gadour, E. & Kotb, A. Systematic review of antifungal-induced acute liver failure. Cureus 13, e18940 (2021).
Spernovasilis, N. & Kofteridis, D. P. Pre-existing liver disease and toxicity of antifungals. J. Fungi (Basel) 4, 133 (2018).
Craven, L. et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am. J. Gastroenterol. 115, 1055–1065 (2020).
Allegretti, J. R. et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial. Am. J. Gastroenterol. 114, 1071–1079 (2019).
Chauhan, A. et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic Hepatitis B patients: A pilot study. Dig. Dis. Sci. 66, 873–880 (2021).
Acharya, S. & Thirunavukkarasu, C. Gut microbiome and cancer: From cancer development to therapeutics with a special focus on hepatocellular carcinoma. Front Biosci. (Landmark Ed.) 29, 67 (2024).
Bajaj, J. S. et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo-controlled trial. Hepatology 70, 1690–1703 (2019).
Philips, C. A., Ahamed, R., Rajesh, S., Abduljaleel, J. K. P. & Augustine, P. Long-term outcomes of stool transplant in alcohol-associated hepatitis-analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care. J. Clin. Exp. Hepatol. 12, 1124–1132 (2022).
Philips, C. A. et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: A pilot study. Clin. Gastroenterol. Hepatol. 15, 600–602 (2017).
Sharma, A. et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial. Hepatol. Int 16, 433–446 (2022).
Xue, L., Deng, Z., Luo, W., He, X. & Chen, Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial. Front Cell Infect. Microbiol 12, 759306 (2022).
Yadegar, A. et al. Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host Microbe 31, 695–711 (2023).
Sheng, L. et al. Hepatic inflammation caused by dysregulated bile acid synthesis is reversible by butyrate supplementation. J. Pathol. 243, 431–441 (2017).
Zuo, T. et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 9, 3663 (2018).
Danne, C., Rolhion, N. & Sokol, H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat. Rev. Gastroenterol. Hepatol. 18, 503–513 (2021).
DeFilipp, Z. et al. Drug-Resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
Bajaj, J. S., Ng, S. C. & Schnabl, B. Promises of microbiome-based therapies. J. Hepatol. 76, 1379–1391 (2022).
Hoffmann, C. et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 8, e66019 (2013).
Costabile, A. et al. Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: A double-blind, placebo-controlled, crossover study. Br. J. Nutr. 99, 110–120 (2008).
Carvalho-Wells, A. L. et al. Determination of the in vivo prebiotic potential of a maize-based whole grain breakfast cereal: A human feeding study. Br. J. Nutr. 104, 1353–1356 (2010).
Rühlemann, M. C. et al. Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species. Gut 69, 1890–1892 (2020).
Lemoinne, S. et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut 69, 92–102 (2020).